$CHHE
China Health Industries Holdings, Inc.

2023 Q4 Form 10-K Financial Statement

#000121390023085612 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q2 2023
Revenue $50.00 $57.51K $111.6K
YoY Change -99.85% 21200.0% 41689.89%
Cost Of Revenue $50.00 $62.63K $111.4K
YoY Change -99.83% 3478.86% 6270.65%
Gross Profit $0.00 -$5.120K $220.00
YoY Change -100.0% 245.95% -114.85%
Gross Profit Margin 0.0% -8.9% 0.2%
Selling, General & Admin $362.6K $574.4K $1.285M
YoY Change 62.26% -38.57% 37.48%
% of Gross Profit 584233.18%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $82.95K $159.3K $557.5K
YoY Change -56.88% -22.73% -21.64%
% of Gross Profit 253412.73%
Operating Expenses $445.6K $604.5K $1.843M
YoY Change 7.15% -63.29% 11.93%
Operating Profit -$445.6K -$609.6K -$1.843M
YoY Change 7.92% -63.01% 11.81%
Interest Expense -$20.00 $26.24K $113.6K
YoY Change -83.38%
% of Operating Profit
Other Income/Expense, Net $30.00 -$8.000K $1.434M
YoY Change -100.0% -100.7% 10.56%
Pretax Income -$445.6K -$591.3K -$408.8K
YoY Change -147.95% 68.46% 16.45%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$445.6K -$591.3K -$408.8K
YoY Change -147.95% 67.07% 15.49%
Net Earnings / Revenue -891120.0% -1028.24% -366.35%
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01 -$0.01
COMMON SHARES
Basic Shares Outstanding 65.54M shares 65.54M shares 65.54M shares
Diluted Shares Outstanding 65.54M shares 65.54M shares

Balance Sheet

Concept 2023 Q4 2023 Q2 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.34K $47.25K $47.25K
YoY Change -99.96% -99.89% -99.89%
Cash & Equivalents $15.34K $47.25K $47.25K
Short-Term Investments
Other Short-Term Assets $226.1K $40.88M $40.88M
YoY Change -8.42% 16591.38% 16591.38%
Inventory $2.390K $40.61K $40.61K
Prepaid Expenses $8.606K
Receivables $0.00 $0.00
Other Receivables $5.620K $1.921K $1.920K
Total Short-Term Assets $249.5K $40.97M $40.97M
YoY Change -99.43% -10.15% -10.15%
LONG-TERM ASSETS
Property, Plant & Equipment $3.043M $2.727M $3.147M
YoY Change 3.06% -13.64% -15.79%
Goodwill
YoY Change
Intangibles $972.3K $964.8K
YoY Change -14.61% -31.7%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.015M $4.112M $4.112M
YoY Change -13.81% -20.16% -20.16%
TOTAL ASSETS
Total Short-Term Assets $249.5K $40.97M $40.97M
Total Long-Term Assets $4.015M $4.112M $4.112M
Total Assets $4.265M $45.08M $45.08M
YoY Change -91.21% -11.16% -11.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $293.0K $286.9K $286.9K
YoY Change -8.18% -14.35% -14.35%
Accrued Expenses $114.8K $90.99K $90.99K
YoY Change 0.46% -43.98% -43.98%
Deferred Revenue
YoY Change
Short-Term Debt $5.652M $5.154M $5.154M
YoY Change -0.33% -23.75% -23.75%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.555M $5.973M $5.973M
YoY Change 0.8% -24.82% -24.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.555M $5.973M $5.973M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $6.555M $5.973M $5.973M
YoY Change 0.8% -24.82% -24.82%
SHAREHOLDERS EQUITY
Retained Earnings $40.66M $41.29M
YoY Change -3.58% -0.98%
Common Stock $528.5K $528.5K
YoY Change 7964.4% 7964.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.290M $39.11M $39.11M
YoY Change
Total Liabilities & Shareholders Equity $4.265M $45.08M $45.08M
YoY Change -91.21% -11.16% -11.16%

Cashflow Statement

Concept 2023 Q4 2023 Q2 2023
OPERATING ACTIVITIES
Net Income -$445.6K -$591.3K -$408.8K
YoY Change -147.95% 67.07% 15.49%
Depreciation, Depletion And Amortization $82.95K $159.3K $557.5K
YoY Change -56.88% -22.73% -21.64%
Cash From Operating Activities -$300.00 -$42.76M -$42.27M
YoY Change -100.06% 4894.6% -2098.01%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.850K $0.00 $0.00
YoY Change
Cash From Investing Activities $2.850K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -300.0 -42.76M -$42.27M
Cash From Investing Activities 2.850K 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash 2.550K -42.76M -$44.74M
YoY Change -99.52% 4894.6% -10194.13%
FREE CASH FLOW
Cash From Operating Activities -$300.00 -$42.76M -$42.27M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
000-51060
CY2023 dei Entity Registrant Name
EntityRegistrantName
CHINA HEALTH INDUSTRIES HOLDINGS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-0827216
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
3199-1 Longxiang Road
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Songbei District
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Harbin City
CY2023 dei Entity Address Country
EntityAddressCountry
CN
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
150028
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Public Float
EntityPublicFloat
7655533 usd
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65539737 shares
CY2023 dei Auditor Firm
AuditorFirmId
6783
CY2023 dei Auditor Name
AuditorName
Assentsure PAC
CY2023 dei Auditor Location
AuditorLocation
Bencoolen, Singapore
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47246 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44789999 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9567 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
40608 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
521229 usd
CY2023Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1921 usd
CY2022Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
31778 usd
CY2023Q2 chhe Advances To Suppliers
AdvancesToSuppliers
198157 usd
CY2022Q2 chhe Advances To Suppliers
AdvancesToSuppliers
214915 usd
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
40682360 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
30004 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
40970292 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
45597492 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2727170 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3158021 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
964775 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1412603 usd
CY2023Q2 chhe Construction In Progress
ConstructionInProgress
420092 usd
CY2022Q2 chhe Construction In Progress
ConstructionInProgress
579402 usd
CY2023Q2 us-gaap Assets
Assets
45082329 usd
CY2022Q2 us-gaap Assets
Assets
50747518 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
286902 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
334972 usd
CY2023Q2 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
94293 usd
CY2022Q2 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
82323 usd
CY2023Q2 us-gaap Customer Advances Current
CustomerAdvancesCurrent
208966 usd
CY2022Q2 us-gaap Customer Advances Current
CustomerAdvancesCurrent
472307 usd
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
90990 usd
CY2022Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
162431 usd
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
137585 usd
CY2022Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
133005 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5972760 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7944799 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65539737 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65539737 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65539737 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65539737 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6554 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
6554 usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
521987 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
521987 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2745558 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
538820 usd
CY2023Q2 chhe Statutory Reserves
StatutoryReserves
38679 usd
CY2022Q2 chhe Statutory Reserves
StatutoryReserves
38679 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
41287907 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
41696679 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
39109569 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
42802719 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
39109569 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
42802719 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45082329 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50747518 usd
CY2023 us-gaap Revenues
Revenues
111579 usd
CY2022 us-gaap Revenues
Revenues
267 usd
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
111359 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
1748 usd
CY2023 us-gaap Gross Profit
GrossProfit
220 usd
CY2022 us-gaap Gross Profit
GrossProfit
-1481 usd
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1285313 usd
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
934927 usd
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
557508 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
711515 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
1842821 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
1646442 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-1842601 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-1647923 usd
CY2023 us-gaap Interest Income Operating
InterestIncomeOperating
113615 usd
CY2022 us-gaap Interest Income Operating
InterestIncomeOperating
157860 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1320791 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1139746 usd
CY2023 chhe Bank Charges
BankCharges
577 usd
CY2022 chhe Bank Charges
BankCharges
699 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1433829 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1296907 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-408772 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-351016 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2934 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-408772 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-353950 usd
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
3284378 usd
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
1617972 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3693150 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1971922 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.0062
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.0054
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65539737 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65539737 shares
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
44774641 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-353950 usd
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1617972 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
42802719 usd
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3284378 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
39109569 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-408772 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-353950 usd
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
686676 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
830545 usd
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6403 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-9556 usd
CY2022 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
2860 usd
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-459731 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-215391 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2813 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2288077 usd
CY2023 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-12737 usd
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
114 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-29278 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11024 usd
CY2023 us-gaap Increase Decrease In Receivables Under Repurchase Agreements
IncreaseDecreaseInReceivablesUnderRepurchaseAgreements
42424029 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-19886 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-57912 usd
CY2023 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-171488 usd
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
358179 usd
CY2023 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-374064 usd
CY2022 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-1057059 usd
CY2023 us-gaap Increase Decrease In Other Employee Related Liabilities
IncreaseDecreaseInOtherEmployeeRelatedLiabilities
-61577 usd
CY2022 us-gaap Increase Decrease In Other Employee Related Liabilities
IncreaseDecreaseInOtherEmployeeRelatedLiabilities
-48844 usd
CY2023 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-10320 usd
CY2022 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-40867 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42272498 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2115726 usd
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2470255 usd
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1672471 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-44742753 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
443255 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44789999 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44346744 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47246 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44789999 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
292050000 cny
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
40275537 usd
CY2023Q2 us-gaap Debt Securities Held To Maturity Purchased With Credit Deterioration Amount At Purchase Price
DebtSecuritiesHeldToMaturityPurchasedWithCreditDeteriorationAmountAtPurchasePrice
295000000 cny
CY2023Q2 us-gaap Debt Securities Held To Maturity Purchased With Credit Deterioration Amount At Purchase Price
DebtSecuritiesHeldToMaturityPurchasedWithCreditDeteriorationAmountAtPurchasePrice
40682360 usd
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.001 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.25 pure
CY2023Q2 us-gaap Foreign Currency Exchange Rate Remeasurement1
ForeignCurrencyExchangeRateRemeasurement1
7.8363 pure
CY2022Q2 us-gaap Foreign Currency Exchange Rate Remeasurement1
ForeignCurrencyExchangeRateRemeasurement1
7.8472 pure
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as the Company</span>’<span style="font-family: Times New Roman, Times, Serif">s operating environment changes. Significant estimates and assumptions by management include, among others; useful lives of long-lived assets and intangible assets, valuation of inventory, accounts receivable and notes receivable, impairment analysis of long-lived assets, construction in progress, intangible assets and deferred taxes. While the Company believes that the estimates and assumptions used in the preparation of the financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47246 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44789999 usd
CY2023Q2 chhe Purchase Price Payment Term
PurchasePricePaymentTerm
P15D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.001 pure
CY2023 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9567 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
51188 usd
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
48769 usd
CY2023Q2 chhe Advances To Suppliers
AdvancesToSuppliers
198157 usd
CY2022Q2 chhe Advances To Suppliers
AdvancesToSuppliers
214915 usd
CY2023 chhe Income Tax Services Rate Percentage
IncomeTaxServicesRatePercentage
0.16 pure
CY2023 chhe Value Added Tax Payables
ValueAddedTaxPayables
37119 usd
CY2022 chhe Value Added Tax Payables
ValueAddedTaxPayables
29835 usd
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Concentrations of Business and Credit Risks</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">All of the Company</span>’<span style="font-family: Times New Roman, Times, Serif">s manufacturing is located in the PRC. There can be no assurance that the Company will be able to successfully continue to manufacture its products and failure to do so would have a material adverse effect on the Company</span>’<span style="font-family: Times New Roman, Times, Serif">s financial position, results of operations and cash flows. Moreover, the success of the Company</span>’<span style="font-family: Times New Roman, Times, Serif">s operations is subject to numerous contingencies, some of which are beyond management</span>’<span style="font-family: Times New Roman, Times, Serif">s control. These contingencies include general economic conditions, prices of raw materials, competition, governmental and political conditions, and changes in regulations. Since the Company is dependent on trade in the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company</span>’<span style="font-family: Times New Roman, Times, Serif">s operations will be subject to the risks of restrictions on transfer of funds, domestic customs, changing taxation policies, foreign exchange restrictions, and political and governmental regulations. The Company operates in China, which may give rise to significant foreign currency risks from fluctuations and the degree of volatility of foreign exchange rates between U.S. dollars and the Chinese currency RMB. The results of operations denominated in foreign currency are translated at the average rate of exchange during the reporting periods.</span></p>
CY2014Q4 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
8000000 cny
CY2014Q4 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
1306186 usd
CY2015Q1 chhe Number Of Drug Approval
NumberOfDrugApproval
19 pure
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
292050000 cny
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
40275537 usd
CY2023Q2 us-gaap Debt Securities Held To Maturity Purchased With Credit Deterioration Amount At Purchase Price
DebtSecuritiesHeldToMaturityPurchasedWithCreditDeteriorationAmountAtPurchasePrice
295000000 cny
CY2023Q2 us-gaap Debt Securities Held To Maturity Purchased With Credit Deterioration Amount At Purchase Price
DebtSecuritiesHeldToMaturityPurchasedWithCreditDeteriorationAmountAtPurchasePrice
40682360 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
1769 usd
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
213055 usd
CY2022Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
90303 usd
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
82412 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
575 usd
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
135459 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
38264 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
40608 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
521229 usd
CY2023Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
420092 usd
CY2022Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
579402 usd
CY2012Q2 chhe Estimated Total Cost Of Construction
EstimatedTotalCostOfConstruction
1860000 usd
CY2012Q2 chhe Estimated Total Cost Of Construction
EstimatedTotalCostOfConstruction
12800000 cny
CY2023Q2 chhe Construction In Progress Percentage
ConstructionInProgressPercentage
0.7136 pure
CY2023Q2 chhe Cost Of Construction In Progress
costOfConstructionInProgress
1259608 usd
CY2023Q2 chhe Cost Of Construction In Progress
costOfConstructionInProgress
9133796 cny
CY2023Q2 chhe Construction In Progress Amount
ConstructionInProgressAmount
724409 usd
CY2023Q2 chhe Construction In Progress Amount
ConstructionInProgressAmount
5252904 cny
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-89883 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
84522 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2934 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3771594 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3879752 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2727170 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3158021 usd
CY2023 us-gaap Depreciation
Depreciation
332057 usd
CY2022 us-gaap Depreciation
Depreciation
344919 usd
CY2023 chhe Depreciation Expense Charged To Operations
DepreciationExpenseChargedToOperations
202889 usd
CY2022 chhe Depreciation Expense Charged To Operations
DepreciationExpenseChargedToOperations
344919 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-5004808 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-5050012 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
964775 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1412603 usd
CY2023Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
354619 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
485625 usd
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65539737 shares
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-408772 usd
CY2023Q2 us-gaap Other Liabilities
OtherLiabilities
5154024 usd
CY2022Q2 us-gaap Other Liabilities
OtherLiabilities
6759761 usd
CY2023 us-gaap Realized And Unrealized Gain Loss Investment And Derivative Operating Federal Current Tax Expense Benefit
RealizedAndUnrealizedGainLossInvestmentAndDerivativeOperatingFederalCurrentTaxExpenseBenefit
322053 usd
CY2022 us-gaap Realized And Unrealized Gain Loss Investment And Derivative Operating Federal Current Tax Expense Benefit
RealizedAndUnrealizedGainLossInvestmentAndDerivativeOperatingFederalCurrentTaxExpenseBenefit
223833 usd
CY2023Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
22020 usd
CY2022Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
23839 usd
CY2023Q2 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
37119 usd
CY2022Q2 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
29835 usd
CY2023Q2 us-gaap Accrual For Taxes Other Than Income Taxes Current And Noncurrent
AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent
78446 usd
CY2022Q2 us-gaap Accrual For Taxes Other Than Income Taxes Current And Noncurrent
AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent
79331 usd
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
137585 usd
CY2022Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
133005 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-408772 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-351016 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-85842 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-73714 usd
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
175725 usd
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-7874 usd
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
2934 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2934 usd
CY2022 chhe Total Provision For Income Taxes
TotalProvisionForIncomeTaxes
2934 usd
CY2023Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1007658 usd
CY2022Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1096936 usd
CY2023Q2 chhe Allowance For Doubtful Accounts
AllowanceForDoubtfulAccounts
-12797 usd
CY2022Q2 chhe Allowance For Doubtful Accounts
AllowanceForDoubtfulAccounts
-12192 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
994861 usd
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1084744 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-408772 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-353950 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.0062
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.0054
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65539737 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65539737 shares
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q2 us-gaap Payable Investment Purchase
PayableInvestmentPurchase
68803 usd
CY2023Q2 chhe Number Of Business Segments
NumberOfBusinessSegments
3 pure
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 pure
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Local Phone Number
LocalPhoneNumber
88100688
CY2023 dei City Area Code
CityAreaCode
86-451
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.0054
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.0062
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65539737 shares
CY2023 chhe Loan From Related Party For The Construction Of A Facility
LoanFromRelatedPartyForTheConstructionOfAFacility
usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
CY2023Q2 us-gaap Inventory Adjustments
InventoryAdjustments
usd
CY2022Q2 us-gaap Inventory Adjustments
InventoryAdjustments
usd
CY2023Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
usd
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
usd
CY2023Q2 us-gaap Inventory Net Of Allowances Customer Advances And Progress Billings
InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings
usd
CY2022Q2 us-gaap Inventory Net Of Allowances Customer Advances And Progress Billings
InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings
usd
CY2023 chhe Depreciation Expense Charged To Cost Of Goods Sold
DepreciationExpenseChargedToCostOfGoodsSold
usd
CY2022 chhe Depreciation Expense Charged To Cost Of Goods Sold
DepreciationExpenseChargedToCostOfGoodsSold
usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
usd
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
usd
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
usd
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
usd
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
usd
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
CY2023 chhe Total Provision For Income Taxes
TotalProvisionForIncomeTaxes
usd
CY2023Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.0054
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.0062
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65539737 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65539737 shares
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001309057

Files In Submission

Name View Source Status
chhe-20230630_def.xml Edgar Link unprocessable
chhe-20230630_pre.xml Edgar Link unprocessable
chhe-20230630_lab.xml Edgar Link unprocessable
0001213900-23-085612-index-headers.html Edgar Link pending
0001213900-23-085612-index.html Edgar Link pending
0001213900-23-085612.txt Edgar Link pending
0001213900-23-085612-xbrl.zip Edgar Link pending
chhe-20230630.xsd Edgar Link pending
f10k2023ex23-1_chinahealth.htm Edgar Link pending
f10k2023ex31-1_chinahealth.htm Edgar Link pending
f10k2023ex31-2_chinahealth.htm Edgar Link pending
f10k2023ex32-1_chinahealth.htm Edgar Link pending
f10k2023ex4-2_chinahealth.htm Edgar Link pending
f10k2023_chinahealth.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
chhe-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10k2023_chinahealth_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending